Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

67%

6 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

5(71.4%)

Phase 3

1(14.3%)

N/A

1(14.3%)

7Total

Phase 4(5)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01995370Phase 4Completed

Cilostazol Stroke Prevention Study for Antiplatelet Combination

Role: lead

NCT01176565Phase 3Terminated

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Role: collaborator

NCT02642419Phase 4Unknown

Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study

Role: lead

NCT02633982Unknown

GENERAL;GENeral Practitioners and Embolism pRevention in NVAF Patients Treated With RivAroxaban:reaL-life Evidence

Role: lead

NCT00151229Phase 4Completed

Valsartan in Elderly Isolated Systolic Hypertension Study

Role: collaborator

NCT02129920Unknown

RELAXED: Recurrent Embolism Lessened by Rivaroxaban for Acute Ischemic Stroke

Role: lead

NCT00153946Phase 4Completed

Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke

Role: collaborator

NCT00198562Phase 4Unknown

Hypertension Control Based on Home Blood Pressure

Role: collaborator

NCT00212056Not ApplicableCompleted

Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP

Role: collaborator

All 9 trials loaded